MET and non-small cell lung carcinoma: A phase II clinical trial for advanced NSCLC patients comparing c-Met inhibitor ARQ197 in combination with erlotinib to placebo plus erlotinib demonstrated a significant increase in median PFS of 16.1 weeks for the ARQ197/erlotinib group compared to 9.7 weeks for the placebo/erlotinib group [28].